The global burden of liver disease: The major impact of China

Hepatology

Volumn 60, Issue 6, 2014, Pages 2099-2108

  Wang, Fu Sheng ^a,b   Fan, Jian Gao ^c   Zhang, Zheng ^a   Gao, Bin ^d   Wang, Hong Yang ^e  

^a BEIJING 302 HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^e Eastern Hepatobiliary Surgery Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHINA; CHINESE MEDICINE; GASTROENTEROLOGY; HUMAN; LIVER DISEASES; LIVER TRANSPLANTATION;

CHINA; GASTROENTEROLOGY; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; MEDICINE, CHINESE TRADITIONAL;

EID: 84911921975     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27406     Document Type: Article

References (50)

1. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004;127:S303-S309.
2. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol 2013;28(Suppl 1):7-10.
3. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol 2013;59:160-168.
4. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011;343:d6891.
5. Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol 2013;28(Suppl 1):11-17.
6. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 2012;16:e82-e88.
7. Wang HY, Li D, Liu W, Jin X, Du B, Li YP, et al. Hepatitis B virus subgenotype C2 is the most prevalent subgenotype in northeast China. Clin Microbiol Infect 2010;16:477-481.
8. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-592.
9. Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY, et al. [A sero-epidemiological study on hepatitis C in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2011;32:888-891.
10. Jia L, Yu J, Yang J, Song H, Liu X, Wang Y, et al. HCV antibody response and genotype distribution in different areas and races of China. Int J Biol Sci 2009;5:421-427.
11. Fu Y, Wang Y, Xia W, Pybus OG, Qin W, Lu L, Nelson K. New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. J Viral Hepat 2011;18:42-52.
12. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907-1917.
13. Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011;55:692-701.
14. Liao XW, Ling Y, Li XH, Han Y, Zhang SY, Gu LL, et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther 2011;16:141-147.
15. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014;60:37-45.
16. Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2014;29:545-553.
17. Li YM, Fan JG, Wang BY, Lu LG, Shi JP, Niu JQ, Shen W; Chinese Association for the Study of Liver Disease. Guidelines for the diagnosis and management of alcoholic liver disease: update 2010 (published in Chinese on Chinese Journal of Hepatology 2010; 18: 167-170). J Dig Dis 2011;12:45-50.
18. Zhou L, Conner KR, Phillips MR, Caine ED, Xiao S, Zhang R, Gong Y. Epidemiology of alcohol abuse and dependence in rural chinese men. Alcohol Clin Exp Res 2009;33:1770-1776.
19. Xiang YT, Ma X, Lu JY, Cai ZJ, Li SR, Xiang YQ, et al. Alcohol-related disorders in Beijing, China: prevalence, socio-demographic correlates, and unmet need for treatment. Alcohol Clin Exp Res 2009;33:1111-1118.
20. Liu Y, Zhou LY, Meng XW. Genetic polymorphism of two enzymes with alcoholic liver disease in Northeast China. Hepatogastroenterology 2012;59:204-207.
21. Chen GH, Yang Y, Lu MQ, Cai CJ, Zhang Q, Zhang YC, et al. Liver transplantation for end-stage alcoholic liver disease: a single-center experience from mainland China. Alcohol 2010;44:217-221.
22. Eng MY, Luczak SE, Wall TL. ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature review. Alcohol Res Health 2007;30:22-27.
23. Kwon H, Won Y, Park O, Chang B, Duryee MJ, Thiele GE, et al. Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology 2014;60:146-157.
24. Ji CY, Chen TJ; Working Group on Obesity in China (WGOC). Empirical changes in the prevalence of overweight and obesity among Chinese students from 1985 to 2010 and corresponding preventive strategies. Biomed Environ Sci 2013;26:1-12.
25. Xiao Y, Zhao N, Wang H, Zhang J, He Q, Su D, et al. Association between socioeconomic status and obesity in a Chinese adult population. BMC Public Health 2013;13:355.
26. Fan JG, Zhu J, Li XJ, Chen L, Lu YS, Li L, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 2005;20:1825-1832.
27. Du T, Sun X, Yin P, Huo R, Ni C, Yu X. Increasing trends in central obesity among Chinese adults with normal body mass index, 1993-2009. BMC Public Health 2013;13:327.
28. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, et al.; InterASIA Collaborative Group. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;365:1398-1405.
29. Wang Q, Yin J, Xu L, Cheng H, Zhao X, Xiang H, et al. Prevalence of metabolic syndrome in a cohort of Chinese schoolchildren: comparison of two definitions and assessment of adipokines as components by factor analysis. BMC Public Health 2013;13:249.
30. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al.; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948-59.
31. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al.; American Gastroenterological Association; AmericanAssociation for the Study of Liver Diseases; American College of Gastroenterology. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023.
32. Fan JG, Zhou Q, Wo QH. [Effect of body weight mass and its change on the incidence of nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing Za Zhi 2010;18:676-679.
33. Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409-415.
34. Liew PL, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg 2006;16:1584-1593.
35. Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci 2014;59:2571-2579.
36. Zhang Y, Zhang H, Elizabeth A, Liu XQ. Epidemiology of hepatitis B and associated liver diseases in China. Chin Med Sci J 2013;27:243-248.
37. Xuan SY, Xin YN, Chen H, Shi GJ, Sun Y, Zhang J. [Study on the correlations between HBsAg and hepatitis C virus expression as well as fibrotic staging in hepatocellular carcinoma and pericarcinomatous tissues]. [Article in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2006;27:157-160.
38. Shang QH, Yu JG, Xu CZ, An Y, Liu FY, Sun SC, Zhang GS. [Occult hepatitis B virus infection in chronic viral hepatitis patients with non-A to E hepatitis virus infection]. [Article in Chinese]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2008;22:440-442.
39. Wang FS, Zhang Z. Liver: how can acute-on-chronic liver failure be accurately identified? Nat Rev Gastroenterol Hepatol 2013;10:390-391.
40. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol 2012;57:1336-1348.
41. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al.; CANONIC Study Investigators of the EASL-CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426-1437, 1437.e1-9.
42. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269-282.
43. Globocan. Estimated incidence, mortality and prevalence worldwide in 2012. 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
44. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, He J. The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 2013;32:106-112.
45. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009;16:453-463.
46. Rakela J, Fung JJ. Liver transplantation in China. Liver Transpl 2007;13:182.
47. Chen GH. Liver transplantation in China: retrospect and prospect. Chin Med J (Engl) 2009;122:2229-2230.
48. Zhao P, Wang C, Liu W, Chen G, Liu X, Wang X, et al. Causes and outcomes of acute liver failure in China. PLoS One 2013;8:e80991.
49. China So. A war that China must win. Spotlight on China. Cell Host Microbes 2014;14:5s-12s.
50. Li X, Xu WF. China's efforts to shed its title of "Leader in liver disease". Drug Discov Ther 2007;1:84-85.